Positive News SentimentPositive NewsNASDAQ:UBX Unity Biotechnology (UBX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free UBX Stock Alerts $1.50 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.5850-Day Range$1.50▼$1.9952-Week Range$1.46▼$4.37Volume52,499 shsAverage Volume151,786 shsMarket Capitalization$25.17 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Unity Biotechnology alerts: Email Address Unity Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside333.3% Upside$6.50 Price TargetShort InterestHealthy1.89% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2,023 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.66) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector63rd out of 946 stocksPharmaceutical Preparations Industry23rd out of 434 stocks 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Unity Biotechnology has a forecasted upside of 333.3% from its current price of $1.50.Amount of Analyst CoverageUnity Biotechnology has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.89% of the float of Unity Biotechnology has been sold short.Short Interest Ratio / Days to CoverUnity Biotechnology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unity Biotechnology has recently decreased by 9.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Unity Biotechnology is -0.60. Previous Next 3.1 News and Social Media Coverage News SentimentUnity Biotechnology has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Unity Biotechnology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows5 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,023.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Unity Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 18.45% of the stock of Unity Biotechnology is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to grow in the coming year, from ($2.66) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnity Biotechnology has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Unity Biotechnology Stock (NASDAQ:UBX)Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Read More UBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UBX Stock News HeadlinesFebruary 17, 2024 | finance.yahoo.comUBX Mar 2024 2.000 callFebruary 7, 2024 | uk.investing.comUnity Biotechnology Inc (UBX)March 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.February 6, 2024 | finance.yahoo.comNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossDecember 29, 2023 | finance.yahoo.com10 Supplements for Longevity and Antiaging: Expert RecommendationsDecember 12, 2023 | finance.yahoo.comUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMENovember 27, 2023 | msn.comUnity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63November 17, 2023 | msn.comWedbush Upgrades Unity Biotechnology (UBX)March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.November 16, 2023 | msn.comWedbush upgrades Unity Biotechnology to outperform, cites cash runwayNovember 16, 2023 | finance.yahoo.comCompanies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyNovember 15, 2023 | markets.businessinsider.comUnity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy RatingNovember 14, 2023 | finanznachrichten.deUnity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 14, 2023 | msn.comUnity Biotechnology GAAP EPS of -$1.05 misses by $0.16November 13, 2023 | tmcnet.comUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 13, 2023 | finance.yahoo.comUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 10, 2023 | msn.comUNITY Biotechnology to exercise warrants for $4.38M in gross proceedsNovember 10, 2023 | finance.yahoo.comUNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross ProceedsOctober 25, 2023 | finance.yahoo.comAre Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging PicksOctober 3, 2023 | finance.yahoo.com20 Foods Consumed By Longest Living People Every DaySeptember 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Rockwell Med (RMTI)September 27, 2023 | markets.businessinsider.comUNITY Biotechnology Reports Encouraging Results From Phase 2 ENVISION Study Of UBX1325September 27, 2023 | finance.yahoo.comUNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular DegenerationSeptember 16, 2023 | finance.yahoo.comUnity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 SharesAugust 15, 2023 | finance.yahoo.com20 States With The Longest Life Expectancy In AmericaAugust 9, 2023 | markets.businessinsider.comAnalyst Ratings for Unity BiotechnologyAugust 8, 2023 | finance.yahoo.comUNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business UpdatesSee More Headlines Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/19/2024Next Earnings (Estimated)3/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:UBX CUSIPN/A CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+333.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.92% Return on Assets-45.91% Debt Debt-to-Equity RatioN/A Current Ratio5.74 Quick Ratio5.74 Sales & Book Value Annual Sales$240,000.00 Price / Sales104.88 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book0.32Miscellaneous Outstanding Shares16,780,000Free Float15,963,000Market Cap$25.17 million OptionableOptionable Beta0.88 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Anirvan Ghosh Ph.D. (Age 60)CEO & Director Comp: $1.08MDr. Nathaniel E. David A.B. (Age 56)Ph.D., Co-Founder & Executive Director Comp: $40kMs. Lynne Marie Sullivan (Age 57)CFO & Head of Corporate Development Comp: $730.82kDr. Jan M. van DeursenFounderDr. Judith Campisi Ph.D.FounderMr. Daohong Zhou M.D.FounderMr. Nathan Guz Ph.D.Vice President of OperationsMr. Alexander Azoy (Age 48)Chief Accounting Officer & Principal Accounting Officer Dr. Przemyslaw Sapieha Ph.D.Chief ScientistMr. Alexander Hieu Nguyen J.D. (Age 47)General Counsel & Corporate Secretary More ExecutivesKey CompetitorsLisata TherapeuticsNASDAQ:LSTAAileron TherapeuticsNASDAQ:ALRNBioVieNASDAQ:BIVICalciMedicaNASDAQ:CALCAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 200 shares on 2/15/2024Ownership: 0.000%Armistice Capital LLCBought 688,000 shares on 2/13/2024Ownership: 4.100%Dimensional Fund Advisors LPSold 14,219 shares on 2/7/2024Ownership: 0.152%Simplex Trading LLCBought 200 shares on 2/2/2024Ownership: 0.000%Anirvan GhoshSold 1,183 sharesTotal: $2,022.93 ($1.71/share)View All Insider TransactionsView All Institutional Transactions UBX Stock Analysis - Frequently Asked Questions Should I buy or sell Unity Biotechnology stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UBX shares. View UBX analyst ratings or view top-rated stocks. What is Unity Biotechnology's stock price target for 2024? 4 equities research analysts have issued 12 month price objectives for Unity Biotechnology's stock. Their UBX share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 333.3% from the stock's current price. View analysts price targets for UBX or view top-rated stocks among Wall Street analysts. How have UBX shares performed in 2024? Unity Biotechnology's stock was trading at $1.93 on January 1st, 2024. Since then, UBX stock has decreased by 22.3% and is now trading at $1.50. View the best growth stocks for 2024 here. When is Unity Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our UBX earnings forecast. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology, Inc. (NASDAQ:UBX) announced its earnings results on Wednesday, November, 10th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.60) by $0.60. When did Unity Biotechnology's stock split? Unity Biotechnology's stock reverse split before market open on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). When did Unity Biotechnology IPO? (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Unity Biotechnology's major shareholders? Unity Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.10%), Dimensional Fund Advisors LP (0.15%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anirvan Ghosh and Jamie Dananberg. View institutional ownership trends. How do I buy shares of Unity Biotechnology? Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UBX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.